ArticleInternational journal of clinical and experimental pathology2017
Downregulation of serum miR-140-5p predicts poor prognosis of patients with colorectal cancer.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic and clinicopathological importance of microRNA-140 expression in cancer patients: a meta-analysis.World journal of surgical oncology · 2021Pooled it
- Molecular Pathogenesis of the Coronin Family:International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) have been demonstrated to play a central role in the initiation and development in many types of cancers including colorectal carcinoma (CRC). The purpose of current study was to investigate the clinical significance of serum miR-140-5p in CRC. Real-time PCR was performed to compare the expression level of miR-140-5p in the serum samples from 63 CRC patients, 20 patients with adenomas and 20 healthy controls. Then the clinical significance of serum miR-140-5p was further determined. Serum miR-140-5p was downregulated in the serum samples derived from CRC patients compared to patients with adenomas patients and controls (P<0.01). In addition, its expression level was able to discriminate CRC from adenomas as well as healthy controls with high accuracy, and was also significantly associated with various clinicopathological parameters including TNM stage (P = 0.0013) and lymph node metastasis (P = 0.0323). Serum miR-140-5p was remarkably upregulated in the patients who received surgery (P<0.01). Patients with lower serum miR-140-5p expression suffered poorer 5-year overall survival (P = 0.0034). In conclusion, our study revealed that serum miR-140-5p might function as a tumor suppressor in CRC, which might serve as a novel prognostic biomarker and therapeutic target.
Indexed as
Identifiers
31966825PMC6965953What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.